Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

CJC-1295 (no DAC) cycle length: what human studies ran

Not approved — research use onlyCPreclinical research
Short answer: there is no established CJC-1295 (no DAC) cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • CJC-1295 (no DAC) combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established CJC-1295 (no DAC) cycle length?
No. We found no human studies that report a treatment duration for CJC-1295 (no DAC).
What is the longest human study of CJC-1295 (no DAC)?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
CJC-1295 (no DAC) dosing reference Full research page

References

  1. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog Endocrinology. 2005
  2. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006
  3. Pharmacy Compounding Advisory Committee Meeting, December 4, 2024: FDA presentations on CJC-1295-related bulk drug substances FDA. 2024
  4. Pharmacy Compounding Advisory Committee, December 4, 2024: FDA briefing document and points to consider for CJC-1295-related bulk drug substances FDA. 2024
  5. Substances in Compounding that May Present Significant Safety Risks FDA. 2024
  6. WADA Prohibited List US Food and Drug Administration. 2026
  7. DailyMed drug label search for CJC-1295 (zero labels returned on 22 Oct 2026) DailyMed (NLM). 2026